logo
Sign in

GLAND PHARMA LIMITED (GLAND) financials

GLAND PHARMA LIMITED (GLAND) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to b…

  • Market Cap: ₹50,219Cr.
  • Current Price: ₹3,043
  • Stock P/E: 35.6
  • ROE: 12.8%
  • ROCE: 17.4%
  • Book Value: ₹656
  • Dividend Yield: 0.66%
  • 52W High / Low: ₹3,171/1,574

In Jun 2026, GLAND PHARMA LIMITED (GLAND) reported sales ₹1,287 Cr and net profit ₹364 Cr.

Annual TTM: sales ₹4,800 Cr, net profit ₹1,395 Cr.

Shareholding: Promoters 45.75% (Sep 2026), FIIs 10.36% (Sep 2026), DIIs 33.21% (Sep 2026), Government 0.01% (Sep 2026), Public 10.68% (Sep 2026).

GLAND quarterly results (₹ Cr.)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,0631,0111,0301,0391,0741,1781,2621,287
Expenses699620636680699756754813
Operating Profit364391394359375422508474
OPM %34%39%38%35%35%36%40%37%
Other Income58654455833610659
Interest018374061
Depreciation4244434445454344
Profit before tax380394391362409412565488
Tax %26%25%26%26%26%25%26%25%
Net Profit282295290269302308420364
EPS in Rs17.1017.9117.6016.3418.3318.6925.5222.09
Raw PDF————————
GLAND profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,6333,4634,4013,6174,1674,1164,5524,800
Expenses1,6782,1612,8902,5982,7582,6742,8893,022
Operating Profit9551,3021,5111,0191,4101,4431,6631,778
OPM %36%38%34%28%34%35%37%37%
Other Income139135224184166215279284
Interest73578231811
Depreciation9599110147162169176176
Profit before tax9931,3351,6191,0481,4051,4661,7481,874
Tax %22%25%25%26%26%26%26%—
Net Profit7739971,2127761,0431,0901,3001,395
EPS in Rs49.8860.9473.7847.1163.3466.1478.8884.63
Dividend Payout %0%0%0%0%32%27%25%—
GLAND balance sheet (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1616161616161616
Reserves2,8473,6315,8877,1427,9378,9799,73910,794
Borrowings55554453
Other Liabilities655435588671815542661794
Total Liabilities3,5234,0866,4967,8348,7739,54110,42211,607
Fixed Assets9299689541,5021,5711,6941,7451,688
CWIP12318833819117712042138
Investments00116382,3862,7903,293
Other Assets2,4712,9295,2035,9787,0175,3425,8456,489
Total Assets3,5234,0866,4967,8348,7739,54110,42211,607
GLAND cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1857016057913681,1361,0741,135
Cash from Investing Activity-319-761-1,521-1,0071,211-2,9181,582-74
Cash from Financing Activity-3-71,2383515-7-340-316
Net Cash Flow-136-67322-1811,594-1,7892,316745
Free Cash Flow50530377270145899962917
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit58%99%70%79%67%103%99%93%
GLAND shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters51.83%51.83%51.83%51.83%51.83%51.83%51.77%45.75%
FIIs5.04%6.90%7.39%7.90%7.58%7.29%8.74%10.36%
DIIs34.80%33.27%32.86%32.63%32.99%33.36%30.44%33.21%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%
Public8.33%8.00%7.93%7.63%7.62%7.52%9.06%10.68%
No. of Shareholders1,21,0751,13,7881,10,67197,15194,57891,5001,08,2661,25,667
GLAND key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9083718987103101122
Inventory Days388250312205421253265257
Days Payable190829780128568199
Cash Conversion Cycle289251286214381299284280
Working Capital Days191161169168241224249209
ROCE %27%30%28%25%15%17%16%17%
GLANDUpdated 19 Oct 2026, 5:27

Gland Pharma Limited

Market Cap

₹50,219Cr.

Current Price

₹3,043

High / Low

₹3,171/1,574

Stock P/E

35.6

ROE12.8%
ROCE17.4%
Book Value₹656
Face Value₹1.00
Dividend Yield0.66%

About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days62951031079083718987103101122
Inventory Days283248271283388250312205421253265257
Days Payable5860136161190829780128568199
Cash Conversion Cycle288283239229289251286214381299284280
Working Capital Days141155154185191161169168241224249209
ROCE %22%28%30%22%27%30%28%25%15%17%16%17%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of GLAND PHARMA LIMITED (GLAND)?

The reported market capitalisation for GLAND PHARMA LIMITED (GLAND) is ₹50,219Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of GLAND?

The current price shown for GLAND PHARMA LIMITED (GLAND) on Fincrux is ₹3,043 with a 52-week high/low of ₹3,171/1,574.

What is the P/E ratio of GLAND PHARMA LIMITED (GLAND)?

The stock P/E for GLAND PHARMA LIMITED (GLAND) is 35.6 on Fincrux, with ROE at 12.8% and ROCE at 17.4%.

What were GLAND latest quarterly results?

For Jun 2026, GLAND PHARMA LIMITED (GLAND) reported sales ₹1,287 Cr and net profit ₹364 Cr (figures in ₹ crore unless noted).

What are GLAND annual sales and net profit?

For TTM, GLAND PHARMA LIMITED (GLAND) shows sales of ₹4,800 Cr and net profit of ₹1,395 Cr on the Fincrux profit & loss statement.

Who owns GLAND PHARMA LIMITED (GLAND)?

Latest shareholding for GLAND PHARMA LIMITED (GLAND) on Fincrux: Promoters 45.75% (Sep 2026), FIIs 10.36% (Sep 2026), DIIs 33.21% (Sep 2026), Government 0.01% (Sep 2026), Public 10.68% (Sep 2026).

Where can I find GLAND PHARMA LIMITED (GLAND) financials?

GLAND PHARMA LIMITED (GLAND) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show GLAND balance sheet and cash flow?

Yes. The GLAND PHARMA LIMITED (GLAND) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:27

Designed & Shipped by Harshit Bansal